Is culture-free pneumonia testing finally viable as Pattern Bioscience nears regulatory submission
Pattern Bioscience advances rapid pneumonia diagnostics toward FDA clearance. Discover what this means for ICU care and antibiotic resistance.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
LivaNova PLC expands sleep apnea eligibility as aura6000 gains FDA approval without CCC limits
LivaNova PLC secures FDA approval for aura6000. Discover how it could reshape sleep apnea treatment and expand patient eligibility.
Medical Devices & Diagnostics
Ibex–HNL Lab Medicine deal signals shift from digital pathology to embedded AI decision support in U.S. diagnostics
Ibex partners with HNL Lab Medicine to deploy AI in prostate cancer diagnostics. Discover what this means for pathology workflows and adoption.
Medical Devices & Diagnostics
Can low-dose radiotherapy reshape osteoarthritis care after Siemens Healthineers’ FDA clearance
Siemens Healthineers expands TrueBeam into osteoarthritis care with FDA clearance. Find out how radiotherapy could reshape chronic pain treatment.
Medical Devices & Diagnostics
AptarGroup enters Phase II POSITS study as delivery partner for ENA Respiratory’s INNA-051 nasal spray
Aptar's UDS Powder system enters ENA Respiratory's POSITS Phase II trial. Analyse what INNA-051 must prove in 2026 and why the device choice matters. Read more.
Medical Devices & Diagnostics
Curi Bio and Battelle commercialise human NMJ assay as GLP-ready alternative to mouse bioassay for botulinum toxin testing
Curi Bio and Battelle partner to commercialise a human NMJ assay for botulinum toxin potency testing. What this changes for NAM adoption and the mouse bioassay. Read more.
Medical Devices & Diagnostics
Can Cleerly’s AI platform replace invasive IVUS? INVICTUS registry data suggest noninvasive parity
Cleerly's INVICTUS registry shows AI-QCT matches IVUS in coronary plaque quantification. Read the clinical analysis.
Medical Devices & Diagnostics
How Exact Sciences is building a multi-platform cancer diagnostics case at AACR 2026
Exact Sciences presents Oncodetect MRD and Cancerguard MCED data at AACR 2026. Analysis of what the new TNBC and multi-biomarker classifier findings mean for clinical adoption.
Medical Devices & Diagnostics
Fulgent Genetics acquires Bako Diagnostics and StrataDx to offset precision diagnostics headwind
Fulgent Genetics closes $56.9M Bako and StrataDx acquisition. What it means for anatomic pathology growth, margin risk, and diagnostic consolidation in 2026.
Medical Devices & Diagnostics
How Alamar Biosciences’ Neuro 220 Panel could reshape biomarker discovery in Alzheimer’s and Parkinson’s research
Discover how Alamar Biosciences’ Neuro 220 Panel could transform CNS biomarker research and accelerate diagnostics and trials.